Viatris Inc
$ 16.29
-7.71%
06 Aug - close price
- Market Cap 18,970,565,000 USD
- Current Price $ 16.29
- High / Low $ 18.39 / 16.22
- Stock P/E N/A
- Book Value 12.59
- EPS -0.28
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE -0.02 %
- 52 Week High 18.39
- 52 Week Low 9.18
About
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Analyst Target Price
$18.44
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-07 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-28 | 2023-11-07 |
| Reported EPS | 0.69 | 0.59 | 0.57 | 0.67 | 0.62 | 0.5 | 0.54 | 0.75 | 0.69 | 0.67 | 0.62 | 0.79 |
| Estimated EPS | 0.62 | 0.5 | 0.52 | 0.62 | 0.56 | 0.49 | 0.572 | 0.68 | 0.68 | 0.67 | 0.65 | 0.74 |
| Surprise | 0.07 | 0.09 | 0.05 | 0.05 | 0.06 | 0.01 | -0.032 | 0.07 | 0.01 | 0 | -0.03 | 0.05 |
| Surprise Percentage | 11.2903% | 18% | 9.6154% | 8.0645% | 10.7143% | 2.0408% | -5.5944% | 10.2941% | 1.4706% | 0% | -4.6154% | 6.7568% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-17 | 2026-03-18 | 2025-12-15 | 2025-09-15 | 2025-06-16 | 2025-03-18 | 2024-12-13 | 2024-09-13 | 2024-06-14 | 2024-03-18 |
| Amount | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTRS
2026-08-07 08:09:24
Viatris reported a strong second quarter with 5% revenue growth and 11% adjusted earnings per share growth, both surpassing FactSet consensus estimates. The company also raised its EPS guidance by 5% at the midpoint, despite shares trading down 3% post-announcement. This performance highlights solid regional results and an improved outlook.
2026-08-07 07:38:35
Kenvue Inc. (KVUE) is the world's largest pure-play consumer health company, having spun off from Johnson & Johnson in May 2023. Recent earnings show rare volume growth despite muted performance in the US and Europe. Analysts continue to evaluate its market position and financial outlook.
2026-08-07 04:18:30
Harrow has entered into a definitive agreement to acquire Tyrvaya (varenicline solution), a dry eye nasal spray treatment, from Viatris Inc. This acquisition aims to expand Harrow's dry eye portfolio, complementing its Vevye franchise by offering a differentiated treatment option with a distinct mechanism of action. The deal involves an upfront cash payment of $30 million and up to $70 million in contingent milestone payments, strengthening Harrow's position in the dry eye disease market.
2026-08-07 01:09:28
Viatris Inc (VTRS) reported strong Q2 2026 results with $3.8 billion in revenues, a 3.5% operational growth year-over-year, and raised its full-year guidance. Key drivers included robust performance in Greater China and advancements in its R&D pipeline. The company also highlighted challenges such as supply disruptions at its Nashik facility and anticipated competitive pressures in developed markets, which are expected to temper growth in the second half of 2026.
2026-08-06 23:09:10
Viatris Inc. (VTRS) has seen its average 12-month price target raised from $18.14 to $18.71 by 7 analysts, suggesting a 6% potential upside from its August 5th closing price. The consensus analyst rating remains a "Buy," with 5 out of 12 analysts recommending a Buy, 6 a Hold, and 1 a Sell.
2026-08-06 22:09:21
Viatris Inc (VTRS) shares fell 7.6% to $16.29, which is still 47.7% above its GF Value of $11.03, indicating the stock is significantly overvalued. The company has a GF Score of 58/100, with weak growth potential, and recent insider selling further suggests a cautious outlook. Investors are advised to exercise caution due to the disparity between market price and intrinsic value.
